NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced significant advancements in the intellectual property backing its AVIM (Atrioventricular Interval Modulation) therapy pipeline. Over the past year, the company has secured 10 new patents for hypertension treatment, bringing its global hypertension-related IP portfolio to 120 issued patents. Additionally, 17 new patents have been granted for the use of AVIM therapy in heart failure, further strengthening the company’s robust intellectual property platform.
The AVIM patent estate now includes 46 issued U.S. patents and 91 international patents, encompassing over 2,100 claims related to hypertension and heart failure. This strategic growth aligns with Orchestra BioMed’s mission to address pressing global health challenges such as high blood pressure, a major risk factor for cardiovascular diseases, and heart failure, which impacts more than 64 million patients worldwide.
“We are very proud of the continued expansion of our intellectual property portfolio supporting AVIM therapy,” said David Hochman, Chairman and CEO of Orchestra BioMed. “This extraordinary array of intellectual property reflects our commitment to delivering innovative device-based therapies that can meet the critical needs of physicians and patients.”
AVIM therapy is currently being evaluated in the BACKBEAT global pivotal study, conducted in collaboration with Medtronic, to treat uncontrolled hypertension in patients who also require pacemakers. The therapy targets a high-risk population with elevated cardiovascular risks, including heart failure, strokes, and myocardial infarctions. Highlighting the potential impact of the therapy, the FDA has recently granted Breakthrough Device Designation for AVIM therapy for the treatment of uncontrolled hypertension in at-risk individuals, marking a major milestone for the innovative approach.
Orchestra BioMed’s patent protection spans key global markets, including the United States, Europe, Japan, and China, ensuring the broad applicability of its technologies. With this growing portfolio and pivotal study underway, the company is setting the stage for breakthroughs in managing hypertension and heart failure, two of the leading contributors to global mortality and healthcare burden.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.